Climate change and pharmaceutical companies pose mutual impacts on each other to ultimately affect human health. Pharmaceutical operations alter climate through emissions and waste disposal, while transformed climate events impact human health through distorted disease patterns and mental well-being. Rising temperatures worsen air quality, exacerbating respiratory conditions, and extreme weather events can harm mental health. Additionally, changes in temperature affect the efficacy of anesthetic drugs during surgery, while their production and use participate in changing climate to close the loop. Furthermore, environmental alterations play a crucial role in the emergence and dissemination of infectious diseases among not only humans but also animals, leading to the augmentation of antibiotic consumption and resistance and provoking a significant global health threat. Climate change not only affects humans but also the aquaculture and livestock industries by affecting the growth, health, and productivity of species. Changes in temperature, precipitation patterns, and ocean acidity disrupt ecosystems and increase susceptibility to diseases in both sectors. Another player in the antibiotic resistance exacerbation is the employment of antibiotics to promote growth in livestock, while increased drug residues in animal tissues further compound the issue. This chapter stresses the pressing necessity for joint efforts to address the interrelated issues of climate change, pharmaceutical practices, and health outcomes. It underscores that tackling planetary warming is crucial for environmental sustainability and the well-being of both humans and animals. Pharmaceutical companies can contribute by adopting sustainable practices and developing new treatments and vaccines. Adaptation strategies are crucial for mitigating climate change’s adverse effects on aquaculture and livestock. Ultimately, collaboration among stakeholders is vital for effectively addressing these complex issues.